价格

Selecta Biosciences, Inc.

ACTIVE

马萨诸塞州米德尔塞克斯县, Massachusetts, 美国www.selectabio.comPublic64 名员工成立于: 2008-01-01

隶属于 Cartesian Therapeutics

概览

试验阶段分布

阶段

试验数

占比

1 期

71.4%

2 期

28.6%

试验状态分布

已完成

85.7%

暂停

14.3%

药物批准

暂无批准数据

资讯

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development

- Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report. - Leading companies in hyperuricemia drug development include LG Chem, Shanton Pharma, InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes. - A significant development occurred in December 2024 when Atom Therapeutics partnered with China Medical System Holdings to commercialize lingdolinurad (ABP-671), a novel URAT1 inhibitor for chronic gout and hyperuricemia in China.

May 8, 2025

返回机构列表

Selecta Biosciences, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（7）

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers

药物批准

资讯

Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development